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Introduction
Distinct signaling pathways have been demonstrated to mediate 
estrogen (E2) action and to directly affect its function. Exam-
ples include the regulation of normal mammary development 
and breast cancer growth. E2 is known to be coupled with 
growth factor–signaling networks to promote enhanced cell 
growth in human breast cancer. Several growth factors and their 
receptors are known to participate in E2 signaling, amongst 
which the EGF receptor (EGFR) family of receptor tyrosine ki-
nases are of particular interest because of their critical involve-
ment in human cancer (Bange et al., 2001; Levin, 2003). Indeed, 
aberrant expression and activation of EGFR is frequently ob-
served in various tumors, especially of the breast and ovary, 
where it correlates with a poorer patient prognosis (Keen and 
Davidson, 2003; Roskoski, 2004). In addition, up-regulation of 
EGFR signaling is thought to be an important mechanism that 
confers antiestrogen resistance of breast cancer, resulting in a 
failure of endocrine therapy (Ali and Coombes, 2002; Nicholson 
et al., 2003).
Multiple lines of evidence have suggested that the inter-
action of EGFR with E2 signaling can occur at various levels. E2 
primarily acts on nuclear estrogen receptors (ERs), leading to 
regulation of gene expression, which was traditionally deemed 
the genotropic action of E2. Many E2-responsive genes are 
 indeed key signaling molecules that participate in EGFR 
 signaling (for review see Levin, 2003). Alternatively, a cell 
membrane–associated form of ER (mER) has been reported to 
couple with and activate various G proteins, and thereby medi-
ate the EGFR transactivation, serving as a nongenotropic effect 
of the ER (Levin, 2003; Razandi et al., 2003). More recently, an 
orphan G protein–coupled receptor (GPCR), GPR30, has been 
suggested to be an intracellular receptor of E2 that specifi cally 
binds E2 with a high affi nity and promotes various rapid E2 
 signaling events, such as Ca2+ mobilization and activation of 
Akt cascades (Revankar et al., 2005; Thomas et al., 2005). In 
 addition, Filardo et al. (2000) reported that E2-induced EGFR 
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mechanism in the regulation of complex biological pro-
cesses, such as cancer development. Estrogen (E2), which 
is a steroid hormone that is intimately implicated in breast 
cancer, has also been suggested to function via EGFR 
transactivation. In this study, we demonstrate that E2-
induced EGFR transactivation in human breast cancer cells 
is driven via a novel signaling system controlled by the lipid 
kinase sphingosine kinase-1 (SphK1). We show that E2 sti-
mulates SphK1 activation and the release of sphingosine 
1-phosphate (S1P), by which E2 is capable of activating 
the S1P receptor Edg-3, resulting in the EGFR transactiva-
tion in a matrix metalloprotease–dependent manner. Thus, 
these fi ndings reveal a key role for SphK1 in the coupling 
of the signals between three membrane-spanning events 
induced by E2, S1P, and EGF. They also suggest a new 
signal transduction model across three individual ligand-
receptor systems, i.e., “criss-cross” transactivation.
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transactivation was mediated via GPR30, suggesting a model of 
EGFR transactivation by E2 similar to that induced by other 
well documented GPCR ligands (Gschwind et al., 2001). How-
ever, as GPR30 was found to be uniquely localized to the endo-
plasmic reticulum (Revankar et al., 2005), whether this 
intracellular receptor coupled with G proteins can directly trans-
activate EGFR and the physiological function of GPR30 
remains to be investigated.
Since fi rst described by Prenzel et al. (1999), the trans-
activation of EGFR by GPCR ligands has been considered an 
important model of cellular signal transduction. Several GPCR li-
gands, including lysophosphatidic acid, thrombin, angiotensin II, 
and endothelin-1, have been documented to transactivate 
EGFR, leading to activation of survival or mitogenic pathways 
(Gschwind et al., 2001). Sphingosine 1-phosphate (S1P), 
which is a recently identifi ed GPCR ligand (Hla et al., 2001), 
has also been shown to induce EGFR transactivation through 
S1P receptors (Kim et al., 2000; Tanimoto et al., 2004). We 
 recently demonstrated that E2 serves as a potent activator of 
sphingosine kinase-1 (SphK1), which is a key enzyme that 
catalyzes the formation of S1P (Sukocheva et al., 2003). We 
also demonstrated that the activation of SphK1–S1P signaling 
participates in the nongenomic action of E2, including intra-
cellular Ca2+ mobilization and ERK1/2 activation (Sukocheva 
et al., 2003). Moreover, SphK1 activity has been shown to reg-
ulate neoplastic cell growth of breast cancer in response to E2 
stimulation at both an in vitro and an in vivo level (Nava et al., 
2002; Sukocheva et al., 2003), suggesting an important role of 
SphK1 in the transmission of E2 signaling in breast cancer cells.
In this study, we provide evidence that not only demon-
strates the capacity of S1P to stimulate EGFR transactivation 
in its own right through the S1P receptors in breast cancer 
cells but also reveals a critical role for SphK1 in mediating E2-
induced EGFR transactivation in an S1P receptor–dependent 
manner. Furthermore, these fi ndings illustrate a novel signal-
ing mechanism, called criss-cross transactivation, which is 
triggered by SphK1 activation that signals  between three indi-
vidual ligand-receptor systems (i.e., E2, S1P, and EGF).
Results
S1P stimulates activation of EGFR 
in MCF-7 cells
Treatment of MCF-7 cells with S1P resulted in signifi cant in-
creases in tyrosine phosphorylation of EGFR in a concentration-
dependent manner (Fig. 1). A signifi cant response to S1P was 
commenced at 1 nmol/liter and peaked at 100 nmol/liter, 
which fi ts well within the range of reported binding affi nities 
to S1P receptors (Hla et al., 2001). In parallel, S1P treatment 
caused a signifi cant increase in ERK1/2 phosphorylation, 
which is a key downstream signaling event of EGFR activa-
tion, in a similar concentration-dependent pattern to the S1P-
induced EGFR phosphorylation (Fig. 1). Time course studies 
showed that S1P induced both EGFR and ERK1/2 phosphory-
lation that peaked at 10–15 min and decreased thereafter, but 
was still evident at 240 min after stimulation (Fig. 1). Collec-
tively, these results demonstrate an ability of S1P to induce 
EGFR activation in MCF-7 cells, which was consistent with 
the observations previously reported in vascular smooth muscle 
cells (Tanimoto et al., 2004) and fi broblasts (Kim et al., 2000).
E2- and S1P-induced EGFR transactivation 
through a common signaling pathway
We have recently reported that E2 was capable of inducing 
SphK1 activation and S1P formation that participated in E2 
nongenomic signaling (Sukocheva et al., 2003). The ability of 
E2 to induce EGFR transactivation has been previously dem-
onstrated (Filardo et al., 2000; Razandi et al., 2003). We 
sought to determine whether S1P could mimic E2 to stimulate 
EGFR transactivation. Treatment of MCF-7 cells with E2 
 resulted in a rapid tyrosine phosphorylation of EGFR and 
ERK1/2 phosphorylation similar to that observed in the S1P-
treated cells (Fig. 2 A). Both E2- and S1P-induced activation 
of EGFR and ERK1/2 were blocked by pertussis toxin (PTX), 
which is a Gi-specifi c inhibitor (Fig. 2 A). In contrast, PTX 
had no effect on EGF-stimulated phosphorylation of EGFR 
and ERK1/2 (Fig. 2 A).
As transactivation of EGFR relies on its internal tyrosine 
kinase activity (Prenzel et al., 1999), we examined whether the 
tyrosine kinase activity is required for E2- or S1P-induced 
EGFR transactivation. In the presence of AG1478, which is 
a specifi c EGFR tyrosine kinase inhibitor, both E2- and S1P-
 induced activation of EGFR and ERK1/2 were abolished 
 completely (Fig. 2 A). Serving as a control, EGF-stimulated 
 autophosphorylation of EGFR was completely inhibited by 
AG1478, supporting its specifi c effect on EGFR activity in 
MCF-7 cells.
Figure 1. S1P transactivates EGFR. MCF-7 cells were stimulated with an 
increasing concentration of S1P for 15 min (left) or 1 μmol/liter S1P for the 
indicated time (right). Cell lysates were subjected to SDS-PAGE, and phos-
phorylation of EGFR and ERK1/2 was assayed by using antibodies spe-
cifi c for phosphorylated-EGFR (p-EGFR) and p-ERK1/2, respectively. The 
histograms represent band intensities that were normalized by total EGFR 
or ERK1/2 levels and expressed as the mean ± SD. n = 5. *, P < 0.01; 
†, P < 0.05, versus nil.
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The Src family of kinases has been reported to play a 
 signaling role in GPCR-mediated transactivation of EGFR 
(Gschwind et al., 2001). Src was also suggested to be required 
for E2-induced EGFR transactivation (Filardo et al., 2000; 
 Razandi et al., 2003). Consistent with these previous studies, 
both E2- and S1P-stimulated activation of EGFR and ERK1/2 
were signifi cantly inhibited by the Src-specifi c inhibitor PP2 
(Fig. 2 A), supporting a role for Src in mediating either E2- or 
S1P-induced transactivation of EGFR.
The shedding of heparin-binding EGF (HB-EGF) upon 
matrix metalloprotease (MMP) activation has also been recog-
nized as an important mechanism in mediating EGFR transacti-
vation by GPCR ligands (Prenzel et al., 1999) or by E2 (Filardo 
et al., 2000; Razandi et al., 2003). Therefore, we examined 
whether HB-EGF shedding was involved in E2- or S1P-induced 
EGFR transactivation. We subjected MCF-7 cells to an acid-
wash step, to reduce background autocrine stimulation, and pre-
treated the cells with the MMP inhibitors o-phenanthroline or 
GM6001. Both E2- and S1P-induced EGFR and ERK1/2 acti-
vation were blocked by these two MMP inhibitors (Fig. 2 B). 
In contrast, the MMP inhibitors had no effect on EGF-induced 
autophosphorylation of EGFR. Furthermore, depletion of HB-
EGF production from the culture media by EGF-neutralizing 
antibodies resulted in a signifi cant inhibition of both E2- and 
S1P-induced EGFR activation (Fig. 2 B). Effi ciency and speci-
fi city of the neutralizing antibodies were demonstrated by the 
inhibition of EGF-stimulated EGFR tyrosine phosphorylation. 
These data suggest that HB-EGF shedding and release are re-
quired for both E2- and S1P-induced EGFR transactivation.
SphK1 activation is involved in E2-induced 
EGFR transactivation
As S1P was able to mimic the effect of E2-stimulated EGFR 
transactivation, and E2 was capable of stimulating S1P pro-
duction upon SphK1 activation, we hypothesized that the E2-
induced EGFR transactivation could be mediated by SphK1 
activation. To test this hypothesis, we used stably transfected 
MCF-7 cell lines overexpressing wild-type SphK1 (SphK1WT), 
dominant-negative SphK1 (SphK1G82D), or empty vector 
alone. Previously, we demonstrated that the baseline SphK 
activity in SphK1WT-transfected cells was 10-fold higher 
than in control cells (Sukocheva et al., 2003). E2 stimulation 
resulted in a rapid increase in SphK activity of approximately 
twofold more than the basal level in both SphK1WT-transfected 
and control MCF-7 cells (Sukocheva et al., 2003). In contrast, 
the SphK1G82D-transfected cells had a similar basal SphK 
 activity to the control cells, whereas E2-stimulated SphK 
activity was completely abolished (Sukocheva et al., 2003). 
Figure 2. S1P mimics E2 to induce EGFR transactivation. 
Serum-starved MCF-7 cells were preincubated for 16 h 
with 100 ng/ml PTX or for 60 min with 50 μmol/liter 
AG1478 and 10 μmol/liter PP2 (A), or the cells were 
pretreated for 60 min with the 20-μmol/liter MMP inhibi-
tor phenanthroline, 50 nmol/liter GM6001, or 15 μg/ml 
of the EGF-neutralizing antibodies (EGF-Ab; B). This was 
followed by stimulation for 15 min with 10 nmol/liter E2, 
1 μmol/liter S1P, or 25 ng/ml EGF. The p-EGFR and 
p-ERK1/2 were then analyzed and quantifi ed as described 
in Fig. 1. Data are the mean ± SD from three independent 
experiments. *, P < 0.01; †, P < 0.05, pretreated versus 
nonpretreated.
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Interestingly, although E2-stimulated tyrosine phosphoryla-
tion of EGFR and ERK1/2 phosphorylation were enhanced in 
SphK1WT- transfected cells, the stimulatory effect of E2 was ab-
rogated in the SphK1G82D transfectants (Fig. 3 A). There were 
no signifi cant differences in total EGFR and their cell-surface 
expression levels between these transfected cell lines (Fig. 3, 
A and B). In contrast, neither EGF nor S1P- stimulated EGFR 
phosphorylation was signifi cantly infl uenced by SphK1G82D. 
Thus, these results suggest a specifi c role for SphK activity in 
the E2- induced EGFR transactivation.
Two human SphK isoforms, SphK1 and SphK2, have been 
identifi ed, and both isoforms account for total cellular SphK 
 activity (Kohama et al., 1998; Liu et al., 2000). To defi ne which 
isoform (if not both) is responsible for the transactivation of 
EGFR, as well as the role of endogenous SphK, we used an 
siRNA strategy to down-regulate each isoform’s expression lev-
els in MCF-7 cells. Endogenous SphK1 and SphK2 levels were 
reduced by 86 and 67%, respectively, after treatment with SphK1- 
or SphK2-specifi c siRNA, compared with cells treated with a 
scrambled siRNA (Fig. 4 A).  The specifi city of these siRNAs 
was demonstrated by their inability to inhibit the alternative iso-
form of SphK and the control gene, glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH). Both SphK1- and SphK2-siRNA 
 decreased the baseline levels of SphK activity by 50%. Whereas 
SphK1-siRNA signifi cantly attenuated SphK activity in re-
sponse to E2 stimulation, the extent of the E2- induced increases 
in SphK activity was not changed by SphK2-siRNA (Fig. 4, 
A and B), suggesting that SphK1 is the key isoform responsible for 
the E2-induced SphK activity. Furthermore, by down-regulating 
SphK1, SphK1-siRNA signifi cantly attenuated the E2-induced 
EGFR and ERK1/2 phosphorylation to an extent that was similar 
to SphK1G82D-transfected cells (Fig. 4 C). In contrast, SphK2-
siRNA had no effect on the E2-induced phosphorylation of 
EGFR and ERK1/2. Again, serving as controls, neither EGF- nor 
S1P-induced EGFR and ERK1/2 phosphorylation were inhibited 
by SphK1- or SphK2-siRNA (Fig. 4 C). Collectively, these data 
suggest a critical role for endogenous SphK1, but not for SphK2, 
in mediating E2-stimulated transactivation of EGFR.
Role of mER and GPR30 in the SphK1-
dependent transactivation of EGFR by E2
Our previous work suggested that the E2-induced SphK1 activa-
tion was likely to be mediated by mER in a G protein–dependent 
manner (Sukocheva et al., 2003). As GPR30, which is an orphan 
GPCR, has been more recently identifi ed as an E2-specifi c 
GPCR (Revankar et al., 2005; Thomas et al., 2005), we sought 
to defi ne the role of GPR30 in E2-induced SphK1 activation. To 
this end, we used GPR30 antisense oligonucleotides (AOs) that 
specifi cally down-regulated GPR30 expression in MCF-7 cells 
(Fig. 5 A).  The cells treated with AO-GPR30 resulted in a sig-
nifi cant reduction of the E2-induced increases in SphK activity 
(Fig. 5 B), suggesting a critical involvement of GPR30 in the 
E2-stimulated SphK1 activation. Serving as a control, AO-
GPR30 had no effect on EGF-induced SphK activity (Fig. 5 B). 
Consistent with our previous study (Sukocheva et al., 2003), 
treatment of cells for 18 h with ICI 182780, which down-
 regulated ERα expression (Fig. 5 C), resulted in a reduction 
of the E2-induced SphK activity similar to that observed in 
the AO-GPR30–treated cells (not depicted). Consequently, the 
E2-induced EGFR and ERK1/2 phosphorylation were signifi -
cantly inhibited by either AO-GPR30 or ICI 182780 (Fig. 5 C). 
In contrast, neither AO-GPR30 nor ICI 182780 had effects on 
the S1P- or EGF-induced EGFR and ERK1/2 phosphorylation. 
Collectively, these data suggest that both GPR30 and ERα are 
capable of mediating SphK1 activation, and the resultant EGFR 
transactivation in response to E2 stimulation.
The S1P receptor Edg-3 is required 
for the E2-induced EGFR transactivation
The biological function of SphK1 relies on its product, S1P, 
which functions chiefl y as a ligand for the Edg family of GPCR 
receptors (Hla et al., 2001; Spiegel and Milstien, 2003). There-
fore, we sought to determine the role for S1P and its receptors 
in the SphK1-dependent EGFR transactivation induced by 
E2. We fi rst examined whether S1P is released upon SphK1 ac-
tivation in cells responding to E2 stimulation. As shown in Fig. 
6 A, in parallel with the elevated intracellular content of S1P, 
Figure 3. Effect of SphK on E2-induced EGFR 
transactivation. (A) Stably transfected MCF-7 
cells overexpressing SphK1WT, SphK1G82D, or 
vector alone were stimulated with 10 nmol/liter 
E2, 1 μmol/liter S1P, or 25 ng/ml EGF for 
15 min. The p-EGFR and p-ERK1/2 were ana-
lyzed and quantifi ed as described in Fig. 1. 
Levels of SphK1WT and SphK1G82D expression 
in the transfected cells are shown in the bottom 
blots. Data are mean ± SD from more than 
three independent experiments. *, P < 0.01; 
†, P < 0.05, SphK1WT or SphK1G82D versus 
vector alone. (B) Flow cytometry profi les show 
the cell-surface expression levels of EGFR in 
the transfected MCF-7 cell lines. A profi le us-
ing control antibodies is indicated (Ctl Ab).
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S1P levels were increased by 86% (P < 0.01) in conditioned 
media (CM) collected from the E2-stimulated MCF-7 cells in 
comparison to that from unstimulated cells.  No increase in S1P 
levels were detected after E2 stimulation in CM from the 
SphK1G82D-transfected cells (Fig. 6 A), indicating that SphK1 
activation is responsible for the elevated S1P production and 
 release from the E2-stimulated cells. Correspondingly, CM 
 derived from the E2-treated cells exhibited a substantially greater 
capacity to stimulate EGFR tyrosine phosphorylation compared 
with the CM from untreated cells (Fig. 6 B). Furthermore, treat-
ment with CM derived from the E2-treated SphK1wt-transfected 
cells that contained high levels of S1P (Fig. 6 A) resulted in a 
further increase in EGFR phosphorylation, whereas CM derived 
from the SphK1G82D transfectants had no detectable effect on 
the EGFR phosphorylation (Fig. 6 B). These results suggest that 
the ability of the CM to stimulate EGFR activation was depen-
dent on its cellular SphK1 activity and the amount of S1P 
 release. To explore this notion further, we used two strategies: 
(a) we lipid stripped CM to remove S1P, and (b) before CM 
stimulation, we treated cells with PTX that has been reported to 
block the majority of S1P receptors (Hla et al., 2001). Either 
lipid-stripped CM or CM pretreated with PTX completely abol-
ished the CM-induced EGFR activation (Fig. 6 B), supporting 
a critical involvement of S1P and its receptors in the E2-
 stimulated transactivation of EGFR.
According to Wang et al. (1999), Edg-3, which is a PTX-
sensitive GPCR, is the predominantly expressed S1P receptor 
in MCF-7 cells. To evaluate the potential role of Edg-3 in E2-
 induced EGFR transactivation, we used the antisense strategy 
to knockdown endogenous Edg-3 expression. Cells transfected 
with AO-Edg3 resulted in a signifi cant down-regulation of 
Edg-3  expression levels (80%; Fig. 7 A).  Correspondingly, 
S1P- induced EGFR tyrosine phosphorylation was also blocked 
by AO-Edg3 (Fig. 7 A). Moreover, treatment of MCF-7 cells 
with AO-Edg3 caused a signifi cant reduction in E2-induced 
EGFR tyrosine phosphorylation, whereas EGF-induced EGFR 
autophosphorylation was retained (Fig. 7 A). Furthermore, as 
a functional consequence, E2-induced cell growth was signifi -
cantly inhibited by AO-Edg3 to a similar extent as that observed 
in cells treated with the EGFR inhibitor AG1478 (Fig. 7 B). 
Collectively, these fi ndings suggest that the S1P receptor Edg-3 
is required for the E2-induced EGFR transactivation and cell 
growth in MCF-7 cells.
Discussion
The current understanding of cell signaling has grown broadly, 
from individual ligand-receptor systems, such as those con-
trolled by GPCR or receptor tyrosine kinases, to an inter-
dependent network that is capable of communicating across 
Figure 4. SphK1, but not SphK2, is responsible for the E2-
induced EGFR transactivation. MCF-7 cells were transfected 
with siRNA specifi c for SphK1, SphK2, or scramble control 
siRNA, as described in Materials and methods. After a 24-h 
transfection, (A) mRNA levels of SphK1, SphK2, and GAPDH 
were determined by RT-PCR, (B) SphK activity was mea-
sured after treatment with 10 nmol/liter E2 for 15 min, and 
(C) p-EGFR and ERK1/2 were analyzed after the indicated 
stimulation, as described in Fig. 1. Data are mean ± SD from 
three to fi ve independent experiments. *, P < 0.01; †, P < 
0.05, SphK1- or SphK2-siRNA versus control siRNA.
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individual signaling systems. One particular example is that 
of EGFR, which can be transactivated by several GPCR lig-
ands (Gschwind et al., 2001). Although the mechanism that 
controls this transactivation remains largely unknown, EGFR 
transactivation has been recognized as an important pathway in 
the regulation of complex biological processes, such as cancer 
 development. In this study, we demonstrate that E2, acting on 
its own receptors (GPR30 and/or mER), results in the activation 
of the S1P-specifi c receptor Edg-3 via SphK1 activation, lead-
ing to EGFR transactivation (summarized in Fig. 8).  To the best 
of our knowledge, this is the fi rst work to describe such a sig-
naling phenomenon, i.e., a given GPCR ligand–mediated (S1P) 
EGFR transactivation is driven by another independent ligand 
(E2), which suggests a new model of criss-cross transactivation 
between three individual ligand-receptor systems.
As described in this study, SphK1, which is the enzyme 
that catalyzes S1P formation, plays an essential role in this 
criss-cross transactivation phenomenon. We have previously 
shown that E2 stimulates SphK1, resulting in both a rapid, 
 transient response and a delayed but prolonged activation 
(Sukocheva et al., 2003). Although the latter response relies on 
ER transcriptional activity, the E2-induced rapid activation of 
SphK1 appears to be necessary for E2 cytoplasmic signaling, 
such as intracellular Ca2+ mobilization and ERK1/2 activation 
(Sukocheva et al., 2003). In addition, cellular SphK activity has 
been functionally linked to the E2-dependent mitogenic and 
carcinogenic action in human breast cancer (Nava et al., 2002; 
Sukocheva et al., 2003), suggesting an important signaling role 
of SphK1 in the biological function of E2. Indeed, SphK1, serv-
ing as an agonist-activated signaling enzyme, has been impli-
cated in a wide spectrum of agonist-driven cellular responses, 
including cell survival, motility, proliferation, and differentia-
tion (Spiegel and Milstein, 2003). This pleiotropic action of 
SphK1 is attributed to its product, S1P, which functions as both 
an intracellular second messenger and a ligand for cell-surface 
receptors (Hla et al., 2001; Spiegel and Milstein, 2003).
S1P receptors belong to the Edg family of GPCR, which 
consists of Edg-1 (also called S1P1), -3 (S1P3), -5 (S1P2), 
-6 (S1P4), and -8 (S1P5; Hla et al., 2001). The identifi cation of 
S1P as a ligand for GPCR has provoked exploration of a poten-
tial role for S1P in the transactivation of receptor tyrosine 
 kinases. Tanimoto et al. (2004) recently reported that S1P was 
capable of inducing transactivation of EGFR and the platelet-
derived growth factor β receptor in vascular smooth muscle 
cells. Consistent with this fi nding, we are able to confi rm that 
Figure 5. Role of GPR30 and ER𝛂 in the E2-induced SphK activity and 
EGFR transactivation. (A) Levels of GPR30 and GAPDH mRNA were deter-
mined by RT-PCR in MCF-7 cells transfected with GPR30 sense oligonucle-
otides or AOs. (B) SphK activity was measured after stimulation for 15 min 
with 10 nmol/liter E2 or 25 ng/ml EGF. (C) Levels of p-EGFR were ana-
lyzed after the indicated stimulation, as described in Fig. 1, in MCF-7 cells 
transfected with GPR30 sense oligonucleotides or AOs or pretreated with 
10 μmol/liter ICI 182780 for 18 h. Expression levels of ERα are shown in 
the bottom blots. Data are mean ± SD from three independent experi-
ments. *, P < 0.01; †, P < 0.05, versus the respective controls.
Figure 6. E2-induced EGFR transactivation is mediated by S1P production. 
(A) Intracellular and extracellular S1P levels were determined in the trans-
fected MCF-7 cells overexpressing SphK1WT, SphK1G82D, or vector alone 
after stimulation with 10 nmol/liter E2 for 15 min. Data are mean ± SD 
from three independent experiments. *, P < 0.01; †, P < 0.05, E2 treated 
versus untreated. (B) MCF-7 cells were pretreated with or without PTX for 
16 h and stimulated for 15 min with lipid-stripped or unstripped CM 
 derived from the transfected MCF-7 cells treated with or without E2. Levels 
of p-EGFR were determined as described in Fig. 1.
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S1P transactivates the EGFR in MCF-7 breast cancer cells, in 
both a time- and dose-dependent manner (Fig. 1). S1P, like 
many other GPCR ligands, induces EGFR transactivation via 
Gi activation of the GPCR and the intrinsic kinase activity of 
EGFR (Gschwind et al., 2001), as demonstrated by the inhibi-
tory effects of PTX and AG1478 on S1P-induced transactiva-
tion of EGFR (Fig. 2). The ability of GPCR ligands to activate 
MMP, resulting in HB-EGF shedding and release, has been 
demonstrated as a necessary event in GPCR-mediated transacti-
vation of EGFR (Prenzel et al., 1999). Although we have not di-
rectly determined the MMP activities and HB-EGF production 
in this study, MMP activation is likely involved in S1P-induced 
EGFR transactivation, as the transactivation of EGFR was 
blocked by either the MMP inhibitors (o-phenanthroline or 
GM6001) or EGF-specifi c neutralizing antibodies (Fig. 2). 
 Additional investigations are needed to determine the effect of 
S1P on MMP activation.
E2, which is a steroid hormone that functions primarily 
through its nuclear receptors (ERα and ERβ), has recently been 
shown to elicit a variety of rapid nongenotropic effects, includ-
ing intracellular Ca2+ mobilization; activation of adenylyl cy-
clase, Raf-1, c-Src, and ERK1/2; and EGFR transactivation 
(Segars and Driggers, 2002; Levin, 2003). These rapid actions 
of E2 are believed to be mediated by its membrane-associated 
receptors. Studies examining the identity of these receptors are 
ongoing, with evidence to suggest that they may be related to 
nuclear ER (Razandi et al., 1999) or the orphan GPCR GPR30 
(Filardo et al., 2000), or form part of a GPCR–ER complex 
(Razandi et al., 2003). More recently, GPR30 has been suggested 
as an E2-specifi c intracellular receptor with a high affi nity and 
a specifi c binding site for E2 (Revankar et al., 2005; Thomas et al., 
2005). In keeping with these fi ndings, we found that down-
 regulation of GPR30 expression in MCF-7 cells by AO-GPR30 
attenuated the E2-induced SphK activity (Fig. 5 B). On the 
other hand, we have previously reported that down-regulation 
of ERα in MCF-7 cells by long-term treatment with ICI 182780 
resulted in a similar inhibition of E2-induced SphK activity 
(Sukocheva et al., 2003), suggesting the involvement of ERα in 
this signaling event. Consequently, E2-induced EGFR trans-
activation was signifi cantly inhibited by either AO-GPR30 or ICI 
182780 in MCF-7 cells (Fig. 5 C). These results suggest the ca-
pacity of both GPR30 and mER, and perhaps of their coopera-
tive actions, to mediate E2-induced SphK1 activation and the 
resultant EGFR transactivation. However, it remains to be de-
fi ned if and how these receptors function cooperatively in 
 transmitting E2 signaling in breast cancer cells.
The role of SphK1 activation in the coupling of E2-
 induced EGFR transactivation was further demonstrated by the 
Figure 7. Effect of Edg-3 on E2-induced EGFR trans-
activation. MCF-7 cells were transfected with Edg-3 sense 
oligonucleotides or AOs, as described in Materials and 
methods. (A) p-EGFR was analyzed after the indicated 
stimulation, as described in Fig. 1. The expression levels 
of Edg-3 are shown in the bottom blots. (B) Cell num-
ber was determined in MCF-7 cells transfected with 
Edg-3 sense oligonucleotides or AOs or pretreated with 
10 μmol/liter AG1478 in the presence or absence of 
10 nmol/liter E2 for 5 d. Data are mean ± SD from three 
independent experiments. *, P < 0.01; †, P < 0.05, 
 versus the control.
Figure 8. Model of E2-induced criss-cross 
transactivation of EGFR through activation of 
the SphK1–S1P signaling pathway. E2, acting 
on its own receptors (GPR30 and/or mER), 
 induces the activation of SphK1 release of S1P 
and the consequent activation of the S1P recep-
tor Edg-3, leading to the EGFR transactivation.
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following series of observations: (a) CM obtained from E2-
stimulated cells that contained higher levels of S1P were capa-
ble of inducing EGFR activation; (b) removal of S1P from CM 
by either lipid stripping or the pretreatment of cells with PTX 
before CM stimulation completely abolished the ability of CM 
to stimulate EGFR phosphorylation; (c) abrogated SphK1 acti-
vation by the expression of SphK1G82D resulted in an attenuation 
of the E2-stimulated EGFR transactivation, whereas S1P-induced 
EGFR transactivation was preserved; (d) down-regulation of 
endogenous SphK1, but not of SphK2, by their specifi c siRNA 
caused a signifi cant inhibition of both SphK1 activation and 
EGFR transactivation in response to E2 stimulation; and fur-
thermore, (e) by down-regulating endogenous Edg-3, which is 
a specifi c receptor for S1P, AO-Edg3 profoundly inhibited the 
E2-induced EGFR transactivation. Thus, we have provided 
compelling evidence to suggest that an autocrine or paracrine 
S1P signaling loop, triggered by SphK1 activation, plays a criti-
cal role in transactivating EGFR through the S1P receptor Edg-3 
in response to E2 stimulation. Despite Edg-3 being previously 
reported as (Wang et al., 1999), and shown to be, the predomi-
nant receptor that accounts for the receptor-dependent action of 
S1P in MCF-7 cells, we are unable to rule out the possibility 
that other members of the S1P receptor family expressed in 
these cells may also be subsidiarily involved in the EGFR trans-
activation. This requires further investigation.
It is noteworthy that by blocking E2-induced SphK1 acti-
vation without alterations in the baseline SphK activity, 
SphK1G82D attenuated the E2-stimulated EGFR transactivation. 
Moreover, although both SphK1- and SphK2-siRNA caused 
a decrease in the basal SphK activity, only SphK1-siRNA that 
inhibited E2-induced SphK1 activity was able to block the 
EGFR transactivation. In contrast, SphK2-siRNA had no effect 
on E2-induced SphK1 activity or EGFR transactivation. These 
results not only suggest a specifi c role for the SphK1 isoenzyme 
but also strongly indicate that the activation of SphK1, rather 
than its baseline activity, is critical for the E2-induced EGFR 
transactivation. In fact, the enzymatic function of SphK1 has 
been suggested to act at two levels: (a) the constitutive basal ac-
tivity is involved in the catabolism of cellular sphingolipids and, 
therefore, may play a housekeeping role (Pitson et al., 2000); 
and (b) the agonist-induced elevated activity is fundamental for 
its signaling role in the regulation of many biological functions, 
including cell survival, proliferation, differentiation, and onco-
genesis (Xia et al., 2000, 2002; Pitson et al., 2000).
Although the detailed mechanism by which E2 induces 
SphK1 activation is currently unknown, E2 was able to stimu-
late SphK1 phosphorylation in an ERK1/2-dependent manner 
(Fig. S1, available at http://www.jcb.org/cgi/content/full/jcb.
200506033/DC1). This is consistent with the fi ndings of Pitson 
et al. (2003) and suggests that ERK1/2-promoted phosphoryla-
tion is required for E2-induced SphK1 activation. Indeed, by 
 inhibiting ERK1/2 activity, the ERK kinase-specifi c inhibitor 
U0126 not only blocked the E2-induced SphK1 phosphoryla-
tion but also signifi cantly attenuated the SphK1-mediated EGFR 
transactivation in response to E2 stimulation (Fig. S2). Interest-
ingly, in addition to the role of ERK1/2 in initiating SphK1 acti-
vation and the resultant EGFR transactivation, inhibition of 
SphK1 activity by either SphK1G82D or SphK1-siRNA resulted 
in a signifi cant attenuation of ERK1/2 activation by E2. The E2-
induced ERK1/2 activation was also inhibited by a blockade of 
EGFR transactivation in MCF-7 cells (Fig. 2), which is in agree-
ment with previous studies (Filardo et al., 2000; Razandi et al., 
2003). Collectively, these observations suggest that ERK1/2 
could be placed upstream or downstream of the SphK1 signal-
ing and has a dual role in the initiation and amplifi cation of a 
positive-feedback signaling loop across E2, SphK1, and EGFR 
in breast cancer cells. However, one question that has been 
raised by these observations is, how does E2 induce an “initial” 
activation of ERK1/2? Recent studies have demonstrated that 
membrane ERα was able to assemble a signalsome complex 
with various signal molecules, such as c-Src (Migliaccio et al., 
1996), the p85 subunit of phosphoinositide 3 kinase (Simoncini 
et al., 2000), or caveolin-1 (Chambliss et al., 2000). Whether 
such complexes directly initiate ERK1/2 activation and the 
methodology to detect the initial signal require further investi-
gation. Nevertheless, as ERK1/2, SphK1, and EGFR all possess 
potent mitogenic signals, this positive-feedback loop could con-
tribute to the aberrant signaling associated with neoplastic cell 
growth. Indeed, inhibition of the SphK1–S1P pathway by ex-
pression of SphK1G82D (Sukocheva et al., 2003) or AO-Edg3 
(Fig. 7 B) resulted in a signifi cant inhibition of breast cancer 
cell growth in response to E2 stimulation, similar to that previ-
ously observed in experiments with the ERK1/2- or EGFR-
 specifi c inhibitors (Bange et al., 2001; Levin, 2003).
In summary, we have demonstrated for the fi rst time 
that SphK1 plays a prominent role in mediating E2’s nonge-
nomic signaling across three membrane-spanning events in-
cluding GPR30/mER, Edg3, and EGFR. Pathways triggered 
by receptor tyrosine kinases have been strongly implicated in 
the pathogenesis and progression of a variety of cancers, such 
as breast cancer (Bange et al., 2001; Levin, 2003). Indeed, 
the retention, up-regulation, and transactivation of EGFR in 
endocrine-resistant or ER-negative tumors have been demon-
strated to be associated with a more aggressive phenotype, high 
disease recurrence rates, and decreased patient survival (Keen 
and Davidson, 2003; Roskoski, 2004). Our previous studies 
have shown an oncogenic potential for SphK1 that is not only 
able to transform rodent fi broblasts and form tumors in nude 
mice (Xia et al., 2000; Pitson et al., 2005) but also able to poten-
tiate the carcinogenic effects of an oncogene, H-Ras (Xia et al., 
2000), in addition to that of E2 (Sukocheva et al., 2003). Thus, 
the fi ndings reported here may represent a specifi c example 
of a general system in which SphK1 plays a coordinating role 
between multiple oncogenic signaling systems. This not only 
elucidates the molecular mechanism responsible for the carci-
nogenic potential of SphK1, but may also provide a potential 
target to create new therapeutic strategies for cancer treatment 
by blocking the SphK1 signaling pathway.
Materials and methods
Cell culture and transfection
Human MCF-7 (ERα+/β+) breast cancer cells were obtained from the 
American Type Culture Collection and cultured in phenol red–free DME 
(CSL Biosciences) containing 10% FBS. Constructs of SphKWT and SphKG82D, 
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and stably transfected MCF-7 cell lines overexpressing SphKWT, SphKG82D, 
or empty vector alone, were previously described (Pitson et al., 2000; 
 Sukocheva et al., 2003).
Experiments with siRNA and AOs
Chemically synthesized siRNA duplexes with 3′-fl uorescein modifi cation 
were purchased from QIAGEN. The siRNA targeted sequences were as fol-
lows: A A G A G C T G C A A G G C C T T G C C C (SphK1), A A C C T C A T C C A G A CA G-
A A C G A (SphK2), and A A T T C T C C G A A C G T G T C A C G T (scrambled control 
siRNA). The following 18-mer phosphothioate oligonucleotides were synthe-
sized by Geneworks: Edg-3 antisense 5′-C G G G A G G G C A G T T G C C A T -3′ 
and sense 5′-A T G G C A A C T G C C C T C C C G -3′; and GPR30 antisense 
5′-T T G G G A A G T C A C A T C C A T -3′ and sense 5′-G A T C T C A G C A C G G C A A A T -3′. 
For transfection, Lipofectamine 2000 reagent (Invitrogen) was used, and 
cells were seeded into 6-well plates at a density of 50,000 cells per well 
1 d before the experiment. After a 36–48-h transfection, the targeted gene 
expression levels were detected by RT-PCR and/or Western blot.
RT-PCR analysis
Total RNA was extracted from cell cultures using TRIzol (Invitrogen). First-
strand cDNA was synthesized from 1 μg total RNA using Omniscript re-
verse transcriptase (QIAGEN) and oligo-dT primer (Geneworks), in a 20 μl 
total volume. SphK1, SphK2, and EdgG-3 were amplifi ed on a PTC-100 
programmable thermal controller (Bio-Rad Laboratories) with an internal 
GAPDH control. The primers used to amplify were as follows: SphK1 sense 
5′-T T G A A C C A T T A T G C T G G C T A T G A and antisense 5′-G C A G G T G T C T T G-
G A A C C C ; SphK2 sense 5′-G C T C A A C T G C T C A C T G T T G C and antisense 
5′-G C A G G T C A G A C A C A G A A C G A ; Edg-3 sense 5′-G C C C T C T C G T G G A-
T T T T G G and antisense 5′-C G C A T G G A G A C G A T C A G T T G ; and GPR30 
sense 5′-C T G G G G A G T T T C C T G T C T G A -3′ and antisense 5′-G C T T G G G A-
A G T C A C A T C C A T -3′. The amplifi ed products were visualized by electro-
phoresis on 1.5% agarose stained with ethidium bromide. Images were 
captured on a gel documentation system (UVitec).
Immunoblot analysis
Cells were harvested and lysed by sonication in lysis buffer containing 50 mM 
Tris/HCl, pH 7.4, 10% glycerol, 0.05% Triton X-100, 150 mM NaCl, 1 mM 
dithiothreitol, 2 mM Na3VO4, 10 mM NaF, 1 mM EDTA, and protease 
 inhibitors (Roche). Aliquots of cell lysates were resolved by 8–12% SDS-
PAGE and transferred to Hybond-P membranes (GE Healthcare). The mem-
branes were then probed with the appropriate antibodies, according to 
manufacturer’s standard method. The immunocomplexes were detected 
with an enhanced chemiluminescence PLUS kit (GE Healthcare). Densitom-
etry was performed on a mode imager (Typhoon 9410; GE Healthcare) 
using the ImageQuant program (Molecular Dynamics).
Assays of SphK activity and S1P measurement
SphK activity was routinely determined by incubating the cytosolic fraction 
with 5 μM D-erythro-sphingosine dissolved in 0.1% Triton X-100 and 
γ-[32P]ATP for 30 min at 37°C, as described previously (Xia et al., 1998). 
The enzyme activity was defi ned as the amount of S1P formation (picomoles 
per minute per milligram of protein). For measurement of S1P, an enzymatic 
method was used as previously reported (Edsall and Spiegel, 1999). After 
E2 stimulation for 30 min, cells and conditional media were collected sepa-
rately and lipids were extracted by alkaline mixture of chloroform and 
 methanol. The basic aqueous fractions containing S1P were incubated with 
alkaline phosphatase for 30 min at 37°C and lipids were extracted twice 
with 1 ml of acidic chloroform. Pooled organic fractions containing newly 
generated sphingosine were dried by vacuum-spin, resuspended in 100 μl 
of reaction buffer, and incubated with recombinant SphK1 and γ-[32P]ATP 
for 30 min at 37°C. The generated [32P]S1P was then resolved by TLC and 
quantifi ed as described previously (Edsall and Spiegel, 1999).
Cell growth assay
MCF-7 cells were transfected with Edg-3 sense or AOs and incubated with or 
without 10 nM E2 in phenol red-free media containing 1% charcoal-treated FBS 
for 5 d. Cell number was then quantifi ed by the MTS assay as described previ-
ously (Sukocheva et al., 2003). The absorbance intensity of the MTS product is 
directly proportional to the number of viable cells in culture when cell number is 
between 2,000 and 200,000, otherwise the exponential dependence was 
 determined. Total cell numbers were calculated based on calibration curves.
Statistical analysis
Unpaired t tests were used for comparison between two groups. For multiple 
comparisons, results were analyzed by analysis of variance, followed by the 
Dunnett’s test. A value of P < 0.05 was considered statistically signifi cant.
Online supplemental material
Fig. S1 shows that E2 stimulated SphK1 phosphorylation in an ERK-
dependent manner. Fig. S2 shows that inhibition of ERK activity by the 
ERK kinase-specifi c inhibitor U0126 resulted in a signifi cant attenuation 
of EGFR phosphorylation in response to E2 stimulation. Online supple-
mental material is available at http://www.jcb.org/cgi/content/full/jcb.
200506033/DC1.
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